3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      A library approach for the de novo high-throughput isolation of humanized VHH domains with favorable developability properties following camelid immunization

      report

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          ABSTRACT

          In this study, we generated a novel library approach for high throughput de novo identification of humanized single-domain antibodies following camelid immunization. To achieve this, VHH-derived complementarity-determining regions-3 (CDR3s) obtained from an immunized llama ( Lama glama) were grafted onto humanized VHH backbones comprising moderately sequence-diversified CDR1 and CDR2 regions similar to natural immunized and naïve antibody repertoires. Importantly, these CDRs were tailored toward favorable in silico developability properties, by considering human-likeness as well as excluding potential sequence liabilities and predicted immunogenic motifs. Target-specific humanized single-domain antibodies (sdAbs) were readily obtained by yeast surface display. We demonstrate that, by exploiting this approach, high affinity sdAbs with an optimized in silico developability profile can be generated. These sdAbs display favorable biophysical, biochemical, and functional attributes and do not require any further sequence optimization. This approach is generally applicable to any antigen upon camelid immunization and has the potential to significantly accelerate candidate selection and reduce risks and attrition rates in sdAb development.

          Related collections

          Most cited references67

          • Record: found
          • Abstract: found
          • Article: not found

          Naturally occurring antibodies devoid of light chains.

          Random association of VL and VH repertoires contributes considerably to antibody diversity. The diversity and the affinity are then increased by hypermutation in B cells located in germinal centres. Except in the case of 'heavy chain' disease, naturally occurring heavy-chain antibodies have not been described, although antigen binding has been demonstrated for separated heavy chains or cloned VH domains. Here we investigate the presence of considerable amounts of IgG-like material of M(r) 100K in the serum of the camel (Camelus dromedarius). These molecules are composed of heavy-chain dimers and are devoid of light chains, but nevertheless have an extensive antigen-binding repertoire, a finding that calls into question the role of light chains in the camel. Camel heavy-chain IgGs lack CH1, which in one IgG class might be structurally replaced by an extended hinge. Heavy-chain IgGs are a feature of all camelids. These findings open new perspectives in the engineering of antibodies.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Biophysical properties of the clinical-stage antibody landscape.

            Antibodies are a highly successful class of biological drugs, with over 50 such molecules approved for therapeutic use and hundreds more currently in clinical development. Improvements in technology for the discovery and optimization of high-potency antibodies have greatly increased the chances for finding binding molecules with desired biological properties; however, achieving drug-like properties at the same time is an additional requirement that is receiving increased attention. In this work, we attempt to quantify the historical limits of acceptability for multiple biophysical metrics of "developability." Amino acid sequences from 137 antibodies in advanced clinical stages, including 48 approved for therapeutic use, were collected and used to construct isotype-matched IgG1 antibodies, which were then expressed in mammalian cells. The resulting material for each source antibody was evaluated in a dozen biophysical property assays. The distributions of the observed metrics are used to empirically define boundaries of drug-like behavior that can represent practical guidelines for future antibody drug candidates.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              The Therapeutic Potential of Nanobodies

              Today, bio-medical efforts are entering the subcellular level, which is witnessed with the fast-developing fields of nanomedicine, nanodiagnostics and nanotherapy in conjunction with the implementation of nanoparticles for disease prevention, diagnosis, therapy and follow-up. Nanoparticles or nanocontainers offer advantages including high sensitivity, lower toxicity and improved safety—characteristics that are especially valued in the oncology field. Cancer cells develop and proliferate in complex microenvironments leading to heterogeneous diseases, often with a fatal outcome for the patient. Although antibody-based therapy is widely used in the clinical care of patients with solid tumours, its efficiency definitely needs improvement. Limitations of antibodies result mainly from their big size and poor penetration in solid tissues. Nanobodies are a novel and unique class of antigen-binding fragments, derived from naturally occurring heavy-chain-only antibodies present in the serum of camelids. Their superior properties such as small size, high stability, strong antigen-binding affinity, water solubility and natural origin make them suitable for development into next-generation biodrugs. Less than 30 years after the discovery of functional heavy-chain-only antibodies, the nanobody derivatives are already extensively used by the biotechnology research community. Moreover, a number of nanobodies are under clinical investigation for a wide spectrum of human diseases including inflammation, breast cancer, brain tumours, lung diseases and infectious diseases. Recently, caplacizumab, a bivalent nanobody, received approval from the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for treatment of patients with thrombotic thrombocytopenic purpura.
                Bookmark

                Author and article information

                Journal
                MAbs
                MAbs
                mAbs
                Taylor & Francis
                1942-0862
                1942-0870
                27 September 2023
                2023
                27 September 2023
                : 15
                : 1
                : 2261149
                Affiliations
                [a ]Antibody Discovery & Protein Engineering, Merck Healthcare KGaA; , Darmstadt, Germany
                [b ]Institute for Organic Chemistry and Biochemistry, Technical University of Darmstadt; , Darmstadt, Germany
                [c ]Early Protein Supply & Characterization, Merck Healthcare KGaA; , Darmstadt, Germany
                [d ]ADCs & Targeted NBE Therapeutics, Merck KGaA; , Darmstadt, Germany
                [e ]Bioinformatics, EMD Serono; , Billerica, MA, USA
                Author notes
                CONTACT Andreas Evers Antibody Andreas.evers@ 123456merckgroup.com Discovery & Protein Engineering, Merck Healthcare KGaA; , Frankfurter Straße 250, Darmstadt D-64293, Germany
                Stefan Zielonka Stefan.zielonka@ 123456merckgroup.com Institute for Organic Chemistry and Biochemistry, Technical University of Darmstadt; , Alarich-Weiss Straße 4, Darmstadt D-64287, Germany
                Author information
                https://orcid.org/0000-0002-4649-2843
                Article
                2261149
                10.1080/19420862.2023.2261149
                10540653
                37766540
                bfe2f977-cccd-4070-be28-8ba78466b61d
                © 2023 The Author(s). Published with license by Taylor & Francis Group, LLC.

                This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License ( http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.

                History
                Page count
                Figures: 5, Tables: 4, References: 68, Pages: 1
                Categories
                Report
                Report

                Immunology
                antibody display,antibody engineering,humanization,in silico developability,library design,ngs,single domain antibody,vhh,yeast surface display

                Comments

                Comment on this article